Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi and Coherus Enter $290 Million Agreement for Junshi's TIGIT Antibody

publication date: Jan 10, 2022

Shanghai Junshi Bio reported Coherus BioSciences, its US partner, will exercise an option to in-license US-Canada rights for Junshi’s TIGIT antibody in an $290 million deal. Coherus will pay Junshi $35 million upfront, up to $255 million in milestones, and an 18% royalty on revenues. In early 2021, Coherus acquired US-Canada rights to Tuoyi (toripalimab), Junshi's PD-1 drug, in a $1.1 billion deal that included the option. Junshi's Tuoyi was the first China-developed anti-PD-1 antibody approved in China. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.